EDVA (EDVA) FinancialsEDVAEDVA

Evaluating the bottom line, Endovia Health Sciences, Inc. maintains a gross margin of 43.75%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -70699.24%, while the net margin is -98126.49%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively EDVA converts its operational activities into shareholder value.

In the context of the broader market, EDVA competes directly with industry leaders such as MNDR and IVF. With a market capitalization of $1.81M, it holds a significant position in the sector. When comparing efficiency, EDVA's gross margin of 43.75% stands against MNDR's 16.94% and IVF's 28.37%. Such benchmarking helps identify whether Endovia Health Sciences, Inc. is trading at a premium or discount relative to its financial performance.

Endovia's financial performance shows troubling signs, with a gross margin of only 29.64% in Q3 2024 and a net margin of -480.68% in the same quarter. The company has not generated significant revenue in subsequent quarters, with total revenue dropping to 4224 in Q1 2026.